Literature DB >> 22710074

Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.

Marjanka J J M Mingels1, Thijs Roelofsen, Jeroen A W M van der Laak, Joanne A de Hullu, Maaike A P C van Ham, Leon F A G Massuger, Johan Bulten, Mijke Bol.   

Abstract

OBJECTIVE: A precursor lesion for ovarian carcinoma, tubal intraepithelial carcinoma (TIC), has been identified in BRCA-mutation carriers undergoing prophylactic bilateral salpingo-oophorectomy (pBSO). Other lesions were also identified in fallopian tubes, but different terminology, interpretation, and lack of knowledge of normal epithelium, have hampered to unravel their possible role in carcinogenesis. The aim of this study is to classify tubal epithelial lesions in BRCA-mutation carriers and controls to enable comparison of prevalence, area of localization, and possible malignant potential.
METHODS: Two hundred twenty-six BRCA1/2-mutation carriers were included; ovaries and fallopian tubes, embedded completely, were reviewed. Controls included 105 women who underwent BSO for non-malignant reasons. Tubal epithelial lesions included the following categories: hyperplasia, minor epithelial atypia, TIC, and invasive carcinoma.
RESULTS: Tubal neoplasia was identified in 7.1% (invasive carcinoma, 0.9%; TIC, 6.2%) of BRCA-mutation carriers compared to none in controls (p=0.004, Fisher's exact test). Hyperplasia and minor epithelial atypia were identified in 41.6% BRCA-mutation carriers and compared to 58.1% in controls (p=0.005, Pearson's chi square). Invasive carcinoma and TIC showed preference for the fimbrial ends (p=0.027, Pearson's chi square), while hyperplasia and minor epithelial atypia displayed more variation in localization.
CONCLUSIONS: Invasive tubal carcinoma and TIC were limited to BRCA-mutation carriers, whereas hyperplasia and minor epithelial atypia were commonly found in both BRCA-mutation carriers and controls. It is suggested that hyperplasia and minor atypia represent variations of normal tubal epithelium instead of premalignant lesions. Furthermore, total salpingectomy is strongly recommended as most but not all TIC occurred in the fimbriae.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22710074     DOI: 10.1016/j.ygyno.2012.06.015

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  20 in total

Review 1.  It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.

Authors:  Ruth Perets; Ronny Drapkin
Journal:  Cancer Res       Date:  2015-12-15       Impact factor: 12.701

2.  Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.

Authors:  James R Conner; Emily Meserve; Ellen Pizer; Judy Garber; Michael Roh; Nicole Urban; Charles Drescher; Bradley J Quade; Michael Muto; Brooke E Howitt; Mark D Pearlman; Ross S Berkowitz; Neil Horowitz; Christopher P Crum; Colleen Feltmate
Journal:  Gynecol Oncol       Date:  2013-12-12       Impact factor: 5.482

Review 3.  Ovarian Cancer Prevention in High-risk Women.

Authors:  Sarah M Temkin; Jennifer Bergstrom; Goli Samimi; Lori Minasian
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

4.  An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.

Authors:  Marie E Perrone; Nicholas P Reder; Sergay N Agoff; Rochelle L Garcia; Kathy J Agnew; Barbara M Norquist; Kathryn P Pennington; Elizabeth M Swisher; Mark R Kilgore
Journal:  Int J Gynecol Pathol       Date:  2020-05       Impact factor: 2.762

Review 5.  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Authors:  Mark E Sherman; Ronny I Drapkin; Neil S Horowitz; Christopher P Crum; Sue Friedman; Janice S Kwon; Douglas A Levine; Ie-Ming Shih; Donna Shoupe; Elizabeth M Swisher; Joan Walker; Britton Trabert; Mark H Greene; Goli Samimi; Sarah M Temkin; Lori M Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-24

6.  Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes.

Authors:  Claire Thompson; Ciara McCormick; Waseem Kamran; Ciaran O'Riain; Lucy Norris; David Gallagher; Noreen Gleeson
Journal:  Ir J Med Sci       Date:  2018-01-03       Impact factor: 1.568

7.  Reported Incidence and Survival of Fallopian Tube Carcinomas: A Population-Based Analysis From the North American Association of Central Cancer Registries.

Authors:  Britton Trabert; Sally B Coburn; Andrea Mariani; Hannah P Yang; Philip S Rosenberg; Gretchen L Gierach; Nicolas Wentzensen; Kathy A Cronin; Mark E Sherman
Journal:  J Natl Cancer Inst       Date:  2018-07-01       Impact factor: 13.506

Review 8.  The tubal epigenome - An emerging target for ovarian cancer.

Authors:  Hunter D Reavis; Ronny Drapkin
Journal:  Pharmacol Ther       Date:  2020-03-18       Impact factor: 12.310

Review 9.  The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin.

Authors:  Mirjana Kessler; Christina Fotopoulou; Thomas Meyer
Journal:  Int J Mol Sci       Date:  2013-03-25       Impact factor: 5.923

10.  Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.

Authors:  Marline G Harmsen; Marieke Arts-de Jong; Nicoline Hoogerbrugge; Angela H E M Maas; Judith B Prins; Johan Bulten; Steven Teerenstra; Eddy M M Adang; Jurgen M J Piek; Helena C van Doorn; Marc van Beurden; Marian J E Mourits; Ronald P Zweemer; Katja N Gaarenstroom; Brigitte F M Slangen; M Caroline Vos; Luc R C W van Lonkhuijzen; Leon F A G Massuger; Rosella P M G Hermens; Joanne A de Hullu
Journal:  BMC Cancer       Date:  2015-08-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.